Jacob Borrajo founded Amber Bio to develop medicines that rewrite large sections of RNA. His work connects gene editing research with biotechnology company building, following doctoral research in the Blainey Lab at the Broad Institute.
Jacob Borrajo founded Amber Bio to develop medicines that rewrite large sections of RNA. His work connects gene editing research with biotechnology company building, following doctoral research in the Blainey Lab at the Broad Institute.
Career
Founder / CEO at Amber Bio from 2021-08 to PresentAVScientific Advisory Board at Alix Ventures from 2019-08 to 2021-09
CAdvisor at Coral from 2018-09 to 2021-09
BIPh.D. Candidate, Blainey Lab at Broad Institute of MIT and Harvard from 2013-09 to 2021-08
SCo-Founder and CEO at Scribio from 2015-05 to 2018-05
Graduate Rotation Student at MIT Media Lab from 2013-12 to 2014-01
Student / Undergraduate Researcher at UCLA from 2011-03 to 2013-06HMHSCI Summer Intern at Harvard Medical School from 2012-06 to 2012-09
Cosigns Received
Vineeta AgarwalaGeneral Partner at Andreessen Horowitz
Jacob and Basem … have built a fast-moving, intensely creative, and yet product-focused team at Amber Bio
)
